Takeda Pharmaceutical Company Limited

BMV:TAK N Stock Report

Market Cap: Mex$859.5b

Takeda Pharmaceutical Past Earnings Performance

Past criteria checks 4/6

Takeda Pharmaceutical has been growing earnings at an average annual rate of 10.3%, while the Pharmaceuticals industry saw earnings growing at 6.2% annually. Revenues have been growing at an average rate of 8.2% per year. Takeda Pharmaceutical's return on equity is 4.2%, and it has net margins of 6.4%.

Key information

10.3%

Earnings growth rate

10.0%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate8.2%
Return on equity4.2%
Net Margin6.4%
Next Earnings Update30 Jan 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Takeda Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BMV:TAK N Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244,546,083289,9961,091,066725,957
30 Jun 244,413,134149,9201,075,736734,339
31 Mar 244,263,762144,0671,053,819728,617
31 Dec 234,169,049178,2191,023,306695,012
30 Sep 234,154,414191,6261,018,085682,260
30 Jun 234,113,631301,3981,013,867652,459
31 Mar 234,027,478317,017997,234633,325
31 Dec 223,944,611274,525965,908616,009
30 Sep 223,749,354213,167934,687569,758
30 Jun 223,591,868197,389897,964547,214
31 Mar 223,569,006230,059886,327526,087
31 Dec 213,465,991438,515897,171495,680
30 Sep 213,401,450473,105888,737484,868
30 Jun 213,345,565431,178892,983471,424
31 Mar 213,197,812376,005875,514455,765
31 Dec 203,199,240180,631895,464486,660
30 Sep 203,221,80456,051921,830491,903
30 Jun 203,243,917119,743928,229486,343
31 Mar 203,291,18844,241964,268492,088
31 Dec 193,236,69713,275965,530485,736
30 Sep 192,876,78283,262867,314440,388
30 Jun 192,496,51163,959790,113407,257
31 Mar 192,097,224135,192692,728368,257
31 Dec 181,780,976110,414608,443317,675
30 Sep 181,769,726140,738616,726321,777
30 Jun 181,772,125120,339622,667321,719
31 Mar 181,770,531186,886628,106325,441
31 Dec 171,785,773190,172632,833324,485
30 Sep 171,762,667163,457622,191314,755
30 Jun 171,746,286160,202616,779310,763
31 Mar 171,732,051114,940615,867311,625
31 Dec 161,729,967132,194614,187312,149
30 Sep 161,754,130150,081627,784332,841
30 Jun 161,795,088155,110633,600337,807
31 Mar 161,807,37880,166650,336335,704
31 Dec 151,831,096-111,874650,103386,767
30 Sep 151,830,521-152,827642,957386,950
30 Jun 151,812,971-154,591637,726387,932
31 Mar 151,777,824-145,775612,489367,741
31 Dec 141,744,79575,405474,242356,593
30 Sep 141,714,694103,390497,474342,907
30 Jun 141,692,531110,981522,831339,169
31 Mar 141,691,685106,658556,210341,560
31 Dec 131,655,033103,3301,036,83110,620

Quality Earnings: TAK N has a large one-off loss of ¥245.4B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: TAK N's current net profit margins (6.4%) are higher than last year (4.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: TAK N's earnings have grown by 10.3% per year over the past 5 years.

Accelerating Growth: TAK N's earnings growth over the past year (51.3%) exceeds its 5-year average (10.3% per year).

Earnings vs Industry: TAK N earnings growth over the past year (51.3%) exceeded the Pharmaceuticals industry 7.7%.

Return on Equity

High ROE: TAK N's Return on Equity (4.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/15 05:55
End of Day Share Price 2024/09/17 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Takeda Pharmaceutical Company Limited is covered by 38 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Hazim BahariCFRA Equity Research